Clinical and microbiologic efficacy and safety profile of linezolid, a new oxazolidinone antibiotic

International Journal of Antimicrobial Agents

Volumn 16, Issue 4, 2000, Pages 527-530

  Corti, Giampaolo ^a   Cinelli, Roberta ^a   Paradisi, Franco ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Antibiotic resistance; Enterococci; Gram positive cocci; Linezolid; Pneumococci; Staphylococci

Indexed keywords

AMPICILLIN; BETA LACTAM ANTIBIOTIC; CHLORAMPHENICOL; GENTAMICIN; LINEZOLID; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOGRAMIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; ASTHENIA; BACTERIAL INFECTION; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; ECONOMIC ASPECT; ENTEROCOCCUS; GRAM POSITIVE COCCI; HEADACHE; HOSPITAL INFECTION; HUMAN; LEUKOPENIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; NAUSEA; NEUTROPENIA; PHLEBITIS; PRIORITY JOURNAL; SKIN MANIFESTATION; STREPTOCOCCUS PNEUMONIAE; THROMBOCYTOPENIA; VERTIGO; VOMITING;

ACETAMIDES; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, MULTIPLE; ENTEROCOCCUS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; STREPTOCOCCUS; TREATMENT OUTCOME;

EID: 0033674053     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(00)00290-9     Document Type: Article

References (31)

1. Major trends in the microbial etiology of nosocomial infection
2. Predominant pathogens in hospital infections
3. Report, data summary from October 1986-April 1996, issued May 1996
4. Nosocomial enterococci resistant to vancomycin - United States, 1989-1993
5. Spread of vancomycin-resistant enterococci: Why did it happen in the US?
6. European glycopeptide susceptibility survey: Susceptibility of Enterococcus spp to teicoplanin and vancomycin
7. Celbenin-resistant staphylococci
8. Nosocomial bloodstream infections in United States hospitals: A three-year analysis
9. Methicillin-resistant Staphylococcus aureus in Europe
10. The prevalence of nosocomial infection in intensive care unit in Europe: Results of the European Prevalence of Infection in Intensive Care (EPIC) study
11. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
12. Emergence of vancomycin resistance in Staphylococcus aureus
13. Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States I. Study on the threat of emerging resistances: Real or perceived?
14. Increasing resistance among Staphylococcus epidermidis isolates in a large teaching hospital over a 12-year period
15. A resistant pneumococcus
16. Emergence of multiply resistant pneumococci
17. Epidemiology and mechanisms of resistance among respiratory tract pathogens
18. Oxazolidinones, a new class of synthetic antibacterials: In vitro and in vivo activities of DuP 105 and DuP 721
19. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials
20. The in-vitro activity of linezolid (U-100766) and tentative breakpoints
21. In-vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin- resistant enterococci
22. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones
23. Comparative in-vitro activities and post-antibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis and Enterococcus faecium
24. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci
25. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin and trovafloxacin and nonquinolones linezolid, quinupristin/dalfopristin, gentamicin and vancomycin against clinical isolates of cip rof loxaci n- resistant and -susceptible Staphylococcus aureus strains
26. Safety and efficacy of linezolid in phase II studies
27. Initial results of linezolid in patients with multi drug resistant gram positive infections
28. Clinical experience with linezolid in a community hospital setting
29. Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin
30. Outcomes with linezolid (LZD) from an ongoing compassionate use (CU) trial of patients with significant, resistant, gram-positive infections
31. Safety and tolerance of linezolid in phase II trials